๐ฐ Iontech News
Page 13 - Iontech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Iontech. Real-time updates on events, politics, business and more.
October 30, 2022
The world could be only a few years away from a usable cancer vaccine, according to the couple who helped to create the Pfizer/BioNtech COVID-19 vaccine
October 30, 2022
The world could be only a few years away from a usable cancer vaccine, according to the couple who helped to create the Pfizer/BioNtech COVID-19 vaccine
October 22, 2022
Updated Covid-19 boosters approved for kids aged 5 to 11, Local News, Newberg local News, Breaking News alerts for Newberg city.
October 20, 2022
NEW YORK CITY (dpa-AFX) - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use or CHMP has recommended marketing authorization for a 3-microgram dose of COMIRNATY
October 17, 2022
The couple who co-founded BioNTech, the pharmaceutical company that partnered with Pfizer to create the COVID-19 vaccine, says that a cancer vaccine could be available by 2030.
October 16, 2022
Given the billions the government is spending on consumption vouchers and free airline tickets, it can pay seniors to get triple-vaccinated, which could save their lives. After doing so, it should scrap all other restrictions, thus safeguarding the economy and peopleโs sanity.
October 16, 2022
German couple Professors Ugur Sahin and Ozlem Tureci said they have had โbreakthroughsโ they will keep working on.
October 13, 2022
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) Thursday announced positive early data from the Phase 2/3 study of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster
October 12, 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their Omicron
October 12, 2022
City officials examining application for approval of second-generation BioNTech coronavirus vaccine designed to target Omicron variant.